Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page
- Check3 days agoChange DetectedThe page has removed key resources related to clinical trials and drug/device information provided by the H. Lee Moffitt Cancer Center, which may impact users seeking important medical information.SummaryDifference0.9%
- Check10 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check17 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check32 days agoChange DetectedThe page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with a revision update to v2.16.1.SummaryDifference1%
- Check39 days agoChange DetectedThe page has been updated to reflect a new version (v2.16.0) and includes new dates for updates, specifically May 20 and May 22, 2025, while removing previous dates from February 2025.SummaryDifference0.7%
Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.